Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
561
Frequently Asked Questions
What is market cap of Intra-Cellular Therapies Inc?
The market cap of Intra-Cellular Therapies Inc is $4.45B
What is the 52 week high for Intra-Cellular Therapies Inc?
The 52 week high for Intra-Cellular Therapies Inc is $66.00.
What is the 52 week low for Intra-Cellular Therapies Inc?
The 52 week low for Intra-Cellular Therapies Inc is $42.01.
What is Intra-Cellular Therapies Inc stock price today?
Intra-Cellular Therapies Inc' stock price today is $46.73.
What is the pe ratio of Intra-Cellular Therapies Inc?
The PE ratio of Intra-Cellular Therapies Inc is -17.13.
What is the price to book ratio of Intra-Cellular Therapies Inc?
The price to book ratio of Intra-Cellular Therapies Inc is 6.7545.
What is Intra-Cellular Therapies Inc's EBITDA?
Intra-Cellular Therapies Inc's EBITDA is -262.97.
What is the 50-day moving average of Intra-Cellular Therapies Inc?
The 50-day moving average of Intra-Cellular Therapies Inc is 47.471.
How many employess does Intra-Cellular Therapies Inc has?